Dianthus Therapeutics Inc
DNTH
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.07B
Close$
$-2.97
102.9% downside
Current Fair Value
102.9% downsideOvervalued by 102.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.07 Billion |
|---|---|
| Enterprise Value | $3.45 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.2 |
| Beta | 0.09 |
| Outstanding Shares | 48,032,742 |
Return
| Return on Equity | -0.94% |
|---|---|
| Return on Assets | -0.91% |
| Return on Invested Capital | -15.84% |
Valuation & Multiples
| P/E Ratio | -887.27 |
|---|---|
| PEG | -2312.49 |
| Price to Sales | - |
| Price to Book Ratio | 4.05 |
| Enterprise Value to Revenue | 3951.87 |
| Enterprise Value to EBIT | -18.02 |
| Enterprise Value to Net Income | -305 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-1.10
Average shareholder expectationRevenue Estimate
$403,615
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
$297,182
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 110.48% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.62%▼ 163.76% |
|---|---|
| Total Invested | $29.13M▼ 99.44% |
| Investors Holding | 7▼ 243.00% |
ESG Score
No data
About Dianthus Therapeutics Inc
81 employees
CEO: Jason Gardner magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of trans...